Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 257

Results For "ABI"

3930 News Found

21.4 lakh TB cases notified in India in 2021
Policy | October 30, 2022

21.4 lakh TB cases notified in India in 2021

Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today


ProBioGen co-develops new Freedom ExpiCHO-S cell line development kit
News | October 28, 2022

ProBioGen co-develops new Freedom ExpiCHO-S cell line development kit

It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.


Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset
News | October 28, 2022

Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset

The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set


USFDA Issues a CRL for the Biologics License Application for Insulin Aspart
Drug Approval | October 27, 2022

USFDA Issues a CRL for the Biologics License Application for Insulin Aspart

The CRL did not identify any outstanding scientific issues with the product.


Laurus Labs planning Rs. 2,000 Cr Capex
News | October 27, 2022

Laurus Labs planning Rs. 2,000 Cr Capex

On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions


Quizartinib granted priority review in the U.S.
Drug Approval | October 26, 2022

Quizartinib granted priority review in the U.S.

Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone


Novartis maintains growth momentum; Confirms FY’22 Group guidance
News | October 26, 2022

Novartis maintains growth momentum; Confirms FY’22 Group guidance

Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.


AstraZeneca updates on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis
Clinical Trials | October 26, 2022

AstraZeneca updates on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis

High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.


Aragen to operationalize Hyderabad formulation manufacturing facility by Jan 2023
News | October 21, 2022

Aragen to operationalize Hyderabad formulation manufacturing facility by Jan 2023

The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting


Aarti Drugs Q2 FY23 revenue up 19%; Profit down 5.6%
News | October 21, 2022

Aarti Drugs Q2 FY23 revenue up 19%; Profit down 5.6%

Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business